Key result
Olmesartan provides sustained 24-hour BP reduction and organoprotection by reducing microvascular inflammation and LVH.
Why the study?
India has a high burden of hypertension that is often poorly controlled and leads to hypertension-mediated organ damage, warranting a review of olmesartan for blood pressure reduction and organoprotection.
Olmesartan is an efficacious angiotensin receptor blocker that provides sustained 24-hour blood pressure control and multiple organoprotective benefits in the management of hypertension.
May support olmesartan for sustained BP control with organoprotection; leaves open randomized trials to confirm benefits.
India has a high burden of hypertension (HTN), which is often poorly controlled, leading to hypertension-mediated organ damage (HMOD). In the management of HTN, angiotensin receptor blockers (ARBs) assume prime importance, being first-line agents for most patient subgroups. Olmesartan is a highly efficacious ARB that demonstrates sustained blood pressure (BP) reduction over 24 hours. Moreover, it also assumes a protective role by reducing microvascular inflammation, left ventricular hypertrophy, proteinuria, vascular stiffness, central aortic BP, cardiocerebrovascular events and atrial fibrillation. To enhance therapeutic compliance and achieve BP goals, single-pill combinations with other antihypertensive agents are also available. This review holistically summarizes the evidence of olmesartan for HTN management for not only BP reduction but also organoprotective effects.
No takes yet. Share an insight, caveat, or question.
Shetty et al. (2024) conducted a review in Hypertension. Olmesartan was evaluated. Olmesartan provides sustained 24-hour blood pressure reduction and organoprotective effects, including reduced microvascular inflammation and left ventricular hypertrophy, in hypertension management.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: